Hướng dẫn phát triển thuốc ức chế topoisomerase I qua mô hình hóa và sàng lọc 3D-QSAR

Castano IB, Brzoska PM, Sadoff BU, Chen H, Christman MF (1996) Mitotic chromosome condensation in the rDNA requires TRF4 and DNA topoisomerase I in Saccharomyces cerevisiae. Genes Dev 10:2564–2576 Lee MP, Brown SD, Chen A, Hsieh TS (1993) DNA topoisomerase I is essential in Drosophila melanogaster. Proc Natl Acad Sci U S A 90:6656–6660 Morham SG, Kluckman KD, Voulomanos N, Smithies O (1996) Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. Mol Cell Biol 16:6804–6809 Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65:635–692 Zhang CX, Chen AD, Gettel NJ, Hsieh TS (2000) Essential functions of DNA topoisomerase I in Drosophila melanogaster. Dev Biol 222:27–40 Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70:369–413 Champoux JJ (1990) Mechanistic aspects of type-I topoisomerases. In: Cozzarelli NR, Wang JC (eds) DNA topology and its biological effects, vol 20. Cold Spring Harbor Laboratory Press, Plainview, New York, pp 217–242 Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430–440 Hertzberg RP, Hecht SM, Caranfa MJ (1989) On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 28:4629–4638 Hertzberg RP, Busby RW, Caranfa MJ, Holden KG, Johnson RK, Hecht SM, Kingsbury WD (1990) Irreversible trapping of the DNA-topoisomerase I covalent complex. Affinity labeling of the camptothecin binding site. J Biol Chem 265:19287–19295 Hsiang YH, Hertzberg RP, Hecht SM, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873–14878 Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351–375 Liu LF, D’Arpa P (1992) Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance. Important Adv Oncol 79–89 Pommier Y, Kohlhagen G, Kohn KW, Leteurtre F, Wani MC, Wall ME (1995) Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc Natl Acad Sci U S A 92:8861–8865 Porter SE, Champoux JJ (1989) The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res 17:8521–8532 Potmesil M, Giovanella BC, Wall ME, Liu LF, Silber R, Stehlin JS, Wani MC, Hochster H (1993) Preclinical and clinical development of DNA topoisomerase I inhibitors in the United States. In: Andoh T, Ikeda H, Oguro M (eds) Molecular biology of DNA topoisomerases and its application to chemotherapy. CRC Press, Boca Raton, pp 301–311 Xu Z, Li T-K, Kim JS, LaVoie EJ, Breslauer KJ, Liu LF, Pilch DS (1998) DNA minor groove binding-directed poisoning of human DNA topoisomerase I by terbenzimidazoles. Biochemistry 37:3558–3566 Bailly C (2000) Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem 7:39–58 Pommier Y (1993) DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother Pharmacol 32:103–108 Bansal S, Sinha D, Singh M, Cheng B, Tse-Dinh Y-C, Tandon V (2012) 3,4-Dimethoxyphenyl bis-benzimidazole, a novel DNA topoisomerase inhibitor that preferentially targets Escherichia coli topoisomerase I. J Antimicrob Chemother 67:2882–2891 Ranjan N, Story S, Fulcrand G, Leng F, Ahmad M, King A, Sur S, Wang W, Tse-Dinh Y-C, Arya DP (2017) Selective inhibition of Escherichia coli RNA and DNA topoisomerase I by Hoechst 33258 derived mono- and bisbenzimidazoles. J Med Chem 60:4904–4922 Kim JS, Sun Q, Yu C, Liu A, Liu LF, LaVoie EJ (1998) Quantitative structure-activity relationships on 5-substituted terbenzimidazoles as topoisomerase I poisons and antitumor agents. Bioorg Med Chem 6:163–172 Mekapati SB, Hansch C (2001) Comparative QSAR studies on bibenzimidazoles and terbenzimidazoles inhibiting topoisomerase I. Bioorg Med Chem 9:2885–2893 Cramer RD, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959–5967 Klebe G (1998) Comparative molecular similarity indices analysis, CoMSIA. Perspect Drug Disc Des 12:87–104 Winkler D (2011) Modelling topoisomerase I inhibition by minor groove binders. Bioorg Med Chem 19:1450–1457 Beerman TA, McHugh MM, Sigmund R, Lown JW, Rao KE, Bathini Y (1992) Effects of analogs of the DNA minor groove binder Hoechst 33258 on topoisomerase II and I mediated activities. Biochim Biophys Acta 1131:53–61 Chen AY, Chiang Y, Gatto B, Liu LF (1993) DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc Natl Acad Sci U S A 90:8131–8135 Pilch DS, Xu Z, Sun Q, LaVoie EJ, Liu LF, Breslauer KJ (1997) A terbenzimidazole that preferentially binds and conformationally alters structurally distinct DNA duplex domains: a potential mechanism for topoisomerase I poisoning. Proc Natl Acad Sci U S A 94:13565–13570 Jin S, Kim JS, Sim S-P, Liu A, Pilch DS, Liu LF, LaVoie EJ (2000) Heterocyclic bibenzimidazole derivatives as topoisomerase I inhibitors. Bioorg Med Chem Lett 10:719–723 Kim JS, Gatto B, Yu C, Liu A, Liu LF, LaVoie EJ (1996) Substituted 2,5’-bi-1H-benzimidazoles: topoisomerase I inhibition and cytotoxicity. J Med Chem 39:992–998 Kim JS, Yu C, Liu A, Liu LF, LaVoie EJ (1997) Terbenzimidazoles: influence of 2″-, 4-, and 5-substituents on cytotoxicity and relative potency as topoisomerase I poisons. J Med Chem 40:2818–2824 Rangarajan M, Kim JS, Jin S, Sim S-P, Liu A, Pilch DS, Liu LF, LaVoie EJ (2000) 2″-Substituted 5-phenylterbenzimidazoles as topoisomerase I poisons. Bioorg Med Chem 8:1371–1382 Rangarajan M, Kim JS, Sim S-P, Liu A, Liu LF, LaVoie EJ (2000) Topoisomerase I inhibition and cytotoxicity of 5-bromo-and 5-phenylterbenzimidazoles. Bioorg Med Chem 8:2591–2600 Sun Q, Gatto B, Yu C, Liu A, Liu LF, LaVoie EJ (1994) Structure activity of topoisomerase I poisons related to Hoechst 33342. Bioorg Med Chem Lett 24:2871–2876 Sun Q, Gatto B, Yu C, Liu A, Liu LF, LaVoie EJ (1995) Synthesis and evaluation of terbenzimidazoles as topoisomerase I inhibitors. J Med Chem 38:3638–3644 Huang CC (1974) Cytogenetic study of human lymphoid T-cell lines derived from lymphocytic leukemia. J Natl Cancer Inst 53:655–660 Wold S, Ruhe A, Wold H, Dunn III WJ (1984) The collinearity problem in linear regression. The partial least squares (PLS) approach to generalized inverses. SIAM J Sci Stat Comp 5:735–743 Wold H (1985) Partial least squares. In: Kotz S, Johnson NL (eds) Encyclopedia of statistical sciences, vol 6. Wiley, New York, pp 581–591 Wold S, Johansson E, Cocchi M (1993) PLS-partial least squares projections to latent structures. In: Kubinyi H (ed) 3D QSAR in drug design: theory, method and applications. ESCOM Science Publishers, Leiden, pp 523–550 Dixon SL, Smondyrev AM, Rao SN (2006) PHASE: a novel approach to pharmacophore modeling and 3D database searching. Chem Biol Drug Des 67:370–372 Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Freisner RA (2006) PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 20:647–671 Teng M-K, Usman N, Frederick CA, Wang AH-J (1988) The molecular structure of the complex of Hoechst 33258 and the DNA dodecamer d(CGCGAATTCGCG). Nucleic Acids Res 16:2671–2690 Issar U, Kumari T, Arora R, Kakkar R (2017) Conformational properties of DNA minor groove binder Hoechst 33258 in gas phase and in aqueous solution. Comp Theo Chem 1113:32–41 Duffy EM, Jorgensen WL (2000) Prediction of properties from simulations: free energies of solvation in hexadecane, octanol, and water. J Am Chem Soc 122:2878–2888 Jorgensen WL, Duffy EM (2000) Prediction of drug solubility from Monte Carlo simulations. Bioorg Med Chem Lett 10:1155–1158 Issar U, Kumari T, Kakkar R (2015) Assessment of molecular binding of Hoechst 33258 analogues into DNA using docking and MM/GBSA approach. J Comp Sci 10:166–177 Kubinyi H (2008) Comparative molecular field analysis (CoMFA). In: Gasteiger J (ed) Handbook of chemoinformatics—from data to knowledge. Wiley-VCH Verlag GmbH, Weinheim, pp 1555–1574 Ray S (2012) QSAR modeling of antitmycobacterial activities of N-benzylsalicylamides and N-benzylsalicylthioamides derivatives against Mycobacterium kansasii CNCTC My (6509/96) using stepwise and PLS method. Int J ChemTech Res 4:41–47 Tenenhaus M, Vinzi VE, Chatelin Y-M, Lauro C (2005) PLS path modeling. Comp Stat Data Anal 48:159–205 Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shaw DE, Shelley M, Perry JK, Francis P, Shenkin PS (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739–1749 Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein−ligand complexes. J Med Chem 49:6177–6196 Giménez BG, Santos MS, Ferrarini M, Fernandes JP (2010) Evaluation of blockbuster drugs under the rule-of-five. Pharmazie 65:148–152 Zhang MQ, Wilkinson B (2007) Drug discovery beyond the ‘rule-of-five’. Curr Opin Biotechnol 18:478–488 Matijević-Sosa J, Cvetnić Z (2005) Antimicrobial activity of N-phthaloylamino acid hydroxamates. Acta Pharma 55:387–399 Michot J-M, Seral C, van Bambeke F, Mingeot-Leclercq M-P, Tulkens PM (2005) Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob Agents Chemother 49:2429–2437 Vandenberg JI, Walker BD, Campbell TJ (2001) HERG K+ channels: friend and foe. Trends Pharmacol Sci 22:240–246 Aronov AM (2005) Predictive in silico modeling for hERG channel blockers. Drug Discov Today 10:149–155 Steinberg M (2007) Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 29:2289–2308 Bellon S, Parsons JD, Wei Y, Hayakawa K, Swenson LL, Charifson PS, Lippke JA, Aldape R, Gross CH (2004) Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase. Antimicrob Agents Chemother 48:1856–1864 Burlison JA, Neckers L, Smith AB, Maxwell A, Blagg BS (2006) Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J Am Chem Soc 128:15529–15536 Lanoot B, Vancanneyt M, Cleenwerck I, Wang L, Li W, Liu Z, Swings J (2002) The search for synonyms among streptomycetes by using SDS-PAGE of whole-cell proteins. Emendation of the species Streptomyces aurantiacus, Streptomyces cacaoi subsp. cacaoi, Streptomyces caeruleus and Streptomyces violaceus. Int J SysT Evol Microbiol 52:823–829 Burris IIIHA (2004) Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 3:10–15 Higa GM, Abraham J (2007) Lapatinib in the treatment of breast cancer. Future Drugs 7:1183–1192 Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1:85–94 Stewart LM, Redinbo MR, Qiu XY, Hol WG, Champoux JJ (1998) A model for the mechanism of human topoisomerase I. Science 279(5356):1534–1541 Khan QA, Pilch DS (2007) Topoisomerase I-mediated DNA cleavage induced by the minor groove-directed binding of bibenzimidazoles to a distal site. J Mol Biol 365:561–569